Momenta Phama (MNTA) Tops Q2 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. HNGE
9. INSP
10. SPY

Go back to Momenta Phama (MNTA) Tops Q2 EPS by 20c

Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results

May 2, 2017 8:00 AM EDT

--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016--

--Ended the first quarter with a strong cash position of $434 million--

CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the first quarter ended March 31, 2017.

We continue to demonstrate the value of our Glatopa business both with increased revenues year-over-year for the 20 mg product and the potential of the 40 mg product to be launched this year, said Craig A. Wheeler,... More